Elliot Norry - Jan 11, 2023 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Signature
/s/ Elliot Norry
Stock symbol
ADAP
Transactions as of
Jan 11, 2023
Transactions value $
-$19,421
Form type
4
Date filed
1/12/2023, 08:01 PM
Previous filing
Jan 4, 2023
Next filing
Jan 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADAP American Depositary Shares representing Ordinary Shares Sale -$6.71K -3.84K -38% $1.75 6.27K Jan 11, 2023 Direct F1, F2, F3
transaction ADAP American Depositary Shares representing Ordinary Shares Sale -$12.7K -7.45K -37.93% $1.71 12.2K Jan 12, 2023 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021, and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.73 to $1.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.
F3 The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 24,336 ADSs and RSU-style options and other options covering an aggregate of 4,664,372 ordinary shares of the Issuer.
F4 Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
F5 The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.70 to $1.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.
F6 The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 24,336 ADSs and RSU-style options and other options covering an aggregate of 4,664,372 ordinary shares of the Issuer.